Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2019 to Jul 2024
GammaCan International, Inc. (OTCBB: GCAN) today
announced that scientists from Tel Ha'Shomer Hospital in Tel Aviv and
GammaCan will present an abstract at the 5th Annual Congress on
Autoimmunity in Sorrento Italy from November 29th through December
3rd, 2006. The study, supported by GammaCan International, under the
direction of Professors Yehuda Shoenfeld, and Miri Blank is entitled
"IgG Decreases Lung Metastatic Potential of Murine (mouse) Colon
Carcinoma."
The researchers will present data examining IgG's (GCAN101)
efficacy in inhibiting the proliferation and metastatic capacity of
colon cancer in a mouse model. Results suggesting that IgG may be
considered a supportive therapy for the inhibition of colon carcinoma
metastases will be included in the abstract discussion.
Prof. Jacob Nusbacher, Director of Medical & Scientific Affairs at
GammaCan commented: "This study confirms other studies that have been
done by GammaCan scientists on other cancers. In the aggregate, these
studies lay the groundwork for the continued development of
immunoglobulin-based anti-cancer therapies, such as we are now doing
with our next generation product, the new anti-melanoma drug,
VitiGam."
About GCAN101
GCAN101 (standard IgG) is currently completing an open label, 30
patient phase II trial designed to evaluate the efficacy and safety of
IgG therapy in cancer patients who failed all current therapies. The
trial is enrolling patients with colon cancer, melanoma and prostate
cancer. The colon and melanoma arms are fully enrolled.
About VitiGam:
VitiGam is GammaCan's second generation intravenous IgG-based
product and a first-in-class anti-cancer immunotherapy. GammaCan plans
on having VitiGam to enter phase I/II testing under a US IND in the
near future after it recently held a pre-IND meeting with the FDA.
VitiGam is being designed to target metastatic melanoma patients with
Stage III and IV melanoma. VitiGam is an IgG product that is different
from standard IgGs: It is manufactured from the plasma of donors with
vitiligo, a benign autoimmune skin condition affecting up to 2% of the
general population. GammaCan scientists have shown that this
"enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma
activity in both in vitro and mouse xenograft melanoma models. Thus,
GammaCan expects VitiGam to provide (1) anti-melanoma activity
directed specifically against malignant melanoma cells and (2)
non-specific anti-cancer activity - as is the case with IgG in
general.
About GammaCan
GammaCan is focusing on the commercialization of an innovative
anti-cancer immunotherapy to treat metastatic cancer. GammaCan's
platform is based on IgG, a safe, relatively non-toxic human
plasma-based product, currently used to treat a variety of immune
deficiencies and autoimmune diseases. IgG works by strengthening the
patient's immune system. Many experts currently view immunotherapy as
a future alternative to today's standard chemotherapy. GammaCan is
developing VitiGam, its second generation program. VitiGam is an IgG
derived from the plasma of vitiligo donors and is being developed to
treat malignant melanoma. GammaCan owns, and has applied for US patent
protection covering the use of IgG and vitiligo-derived IgG (VitiGam).
For more information about GammaCan visit www.GammaCan.com or call
the company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616
or toll free 1-866-308-0396 (from North America).
Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this release
include statements regarding the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IgG into an effective treatment. Actual
outcomes and the Company's actual results could differ materially from
those in such forward-looking statements. Factors that could cause
actual results to differ materially include risks and uncertainties
such as the inability to finance the planned development of the
technology, unforeseen technical difficulties in developing the
technology, the inability to obtain regulatory approval for human use,
competitors' therapies proving more effective, cheaper or otherwise
preferable for consumers, inability to market the product we produce,
among other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further risk
factors see the risk factors associated with other early state medical
research and development companies filed with the SEC on Edgar.